Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,026–4,050 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
· Anticancer Res · 2015 · PMID 25862853 · validated civic_curation pubmed
Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.
· Digestion · 2013 · PMID 24135816 · validated civic_curation pubmed
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.
· Tumour Biol · 2013 · PMID 23881388 · validated civic_curation pubmed
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
· Cell Oncol (Dordr) · 2013 · PMID 23619944 · validated civic_curation pubmed
Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.
· Cancer Lett · 2013 · PMID 23340172 · validated civic_curation pubmed
Class III β-tubulin counteracts the ability of paclitaxel to inhibit cell migration.
· Oncotarget · 2011 · PMID 21576762 · validated civic_curation pubmed
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
· Br J Cancer · 2012 · PMID 22343617 · validated civic_curation

Showing 4,026–4,050 of 4,399 publications

← Previous
1
…
161
162
163
…
176
Next →

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

· Cell Cycle · 2012 · PMID 22262166 · validated civic_curation pubmed

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

· J Pathol · 2012 · PMID 22190288 · validated civic_curation pubmed

Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.

· J Cell Mol Med · 2012 · PMID 22004109 · validated civic_curation pubmed

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.

· J Thorac Oncol · 2011 · PMID 21964527 · validated civic_curation pubmed

Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.

· Clin Cancer Res · 2011 · PMID 21890455 · validated civic_curation pubmed

ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.

· Respirology · 2011 · PMID 21883677 · validated civic_curation pubmed

Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.

· Cancer Sci · 2010 · PMID 20088962 · validated civic_curation pubmed

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.

· Mol Cancer Ther · 2006 · PMID 17088436 · validated civic_curation pubmed

OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer.

· Oncol Rep · 2015 · PMID 26398480 · validated civic_curation pubmed

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.

· Target Oncol · 2016 · PMID 26668065 · validated civic_curation pubmed

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

· Oncotarget · 2015 · PMID 26515464 · validated civic_curation pubmed

NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.

· Oncotarget · 2016 · PMID 26716414 · validated civic_curation pubmed

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

· Oncotarget · 2016 · PMID 26678033 · validated civic_curation pubmed

Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.

· Int J Oncol · 2016 · PMID 26892177 · validated civic_curation pubmed

Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.

· Mol Cancer Res · 2014 · PMID 24962318 · validated civic_curation pubmed

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

· J Clin Invest · 2006 · PMID 16906227 · validated civic_curation pubmed

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

· Cancer Res · 2008 · PMID 18451166 · validated civic_curation pubmed

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

· Clin Cancer Res · 2008 · PMID 18594010 · validated civic_curation pubmed